Delivering precise Alzheimer’s diagnostics.
Enhancing healthcare with the necessary scientific data and empowering millions of patients with more accurate and confident treatment decisions.
Scroll down
SynapsDX is backed by
Up to 30% of Alzheimer's cases may be misdiagnosed. 40% of dementia patients may have a condition other than Alzheimer's, which could be treatable.
6.7MM
People in the US living with AD, expected to rise substantially in the coming years with an aging population.
$12.6B
Global AD diagnostics industry is projected to reach a $12.6B market by the year 2027.
$1T+
The expected annual healthcare cost of AD and other forms of dementia in the U.S. by the year 2050.
Offer DISCERN™ in your practice
Join our group of providers utilizing the DISCERN™ Test, the world’s only Gold Standard validated test for Alzheimer's disease.
Use DISCERN™ in your research
Use the test in your clinical trials to enhance the precision of your research and contribute significantly to the development of effective Alzheimer’s therapies.
Take the test
Uncertain about your symptoms? Learn about DISCERN™, the world's most accurate test available for AD detection.
